Keytruda and Merck jointly bagged another FDA approval against NSCLC

January 26, 2023 – FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer. The Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC).